Guardant Health, Inc. (GH)
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
- Symbol
- GH
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $23.56B
- 52 week range
- 55.38 - 183.51
Valuation
- Share price
- $176.31 (close of 2026-09-23)
- P/E (TTM)
- -50.37x
- Price to book
- -105.70x
- Price to free cash flow
- -97.86x
- Enterprise value
- $24.20B
- Book value per share
- $-1.67
Price performance
| Period | Change |
|---|
| 1 day | +1.40% |
| 5 days | +0.38% |
| 1 month | +3.29% |
| 3 months | +34.76% |
| 6 months | +107.52% |
| Year to date | +72.62% |
| 1 year | +195.23% |
| 3 years | +575.25% |
| 5 years | +35.35% |
| All time | +447.55% |
Profitability and growth
- Return on equity
- 419.18%
- Return on invested capital
- -35.37%
- Return on assets
- -20.67%
- Return on capital employed
- -25.56%
- Gross margin
- 64.46%
- Net margin
- -42.39%
- EBITDA margin
- -40.48%
- Revenue growth
- 32.88%
- Net income growth
- 4.61%
- Free cash flow growth
- 15.23%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -1.02%
- Current ratio
- 4.03x
- Net debt to EBITDA
- -1.57x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $982.02M
- Cost of revenue
- $349.01M
- Gross profit
- $633.01M
- EBITDA
- $-397.51M
- Net income
- $-416.28M
- Earnings per share
- $-3.32
- Research and development
- $364.19M
- Shares outstanding
- 125.37M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $982.02M | $633.01M | $-416.28M | $-3.32 |
| 2024-12-31 | $739.02M | $449.22M | $-436.37M | $-3.56 |
| 2023-12-31 | $563.95M | $336.90M | $-479.45M | $-4.28 |
| 2022-12-31 | $449.54M | $293.21M | $-654.59M | $-6.41 |
| 2021-12-31 | $373.65M | $250.74M | $-384.77M | $-4.00 |
| 2020-12-31 | $286.73M | $194.19M | $-246.28M | $-2.60 |
| 2019-12-31 | $214.38M | $143.66M | $-75.65M | $-0.84 |
| 2018-12-31 | $90.64M | $47.43M | $-85.06M | $-2.80 |
| 2017-12-31 | $49.84M | $18.22M | $-83.22M | $-7.07 |
| 2016-12-31 | $25.25M | $3.13M | $-46.14M | $-3.53 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 64.46% | -42.39% | 419.18% | -35.37% |
| 2024-12-31 | 60.79% | -59.05% | 312.48% | -66.12% |
| 2023-12-31 | 59.74% | -85.02% | -302.14% | -149.04% |
| 2022-12-31 | 65.23% | -145.61% | -1087.72% | -42.27% |
| 2021-12-31 | 67.11% | -102.98% | -59.65% | -104.92% |
| 2020-12-31 | 67.73% | -85.89% | -18.97% | -49.63% |
| 2019-12-31 | 67.01% | -35.29% | -9.48% | -11.57% |
| 2018-12-31 | 52.33% | -93.85% | -17.61% | -27.13% |
| 2017-12-31 | 36.56% | -166.97% | -26.97% | -32.42% |
| 2016-12-31 | 12.38% | -182.74% | -57.89% | -95.10% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $378.20M | $1.50B |
| 2024-12-31 | $525.54M | $1.14B |
| 2023-12-31 | $1.13B | - |
| 2022-12-31 | $141.65M | - |
| 2021-12-31 | $492.20M | - |
| 2020-12-31 | $832.98M | - |
| 2019-12-31 | $143.23M | - |
| 2018-12-31 | $140.54M | - |
| 2017-12-31 | $72.28M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-233.07M | $166.22M |
| 2024-12-31 | $-274.94M | $140.41M |
| 2023-12-31 | $-345.46M | $90.76M |
| 2022-12-31 | $-386.92M | $94.69M |
| 2021-12-31 | $-284.05M | $151.45M |
| 2020-12-31 | $-140.10M | $144.11M |
| 2019-12-31 | $-65.85M | $16.95M |
| 2018-12-31 | $-92.39M | $6.85M |
| 2017-12-31 | $-78.92M | $3.67M |
| 2016-12-31 | $-38.48M | $1.97M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-05-07 | - | - |
| 2026-02-19 | - | - |
| 2025-10-29 | - | - |
| 2025-07-30 | - | - |
| 2025-04-30 | - | - |
| 2025-02-20 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- guardanthealth.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV) · Agilent Technologies, Inc. (A) · Waters Corp (WAT) · IDEXX Laboratories Inc (IDXX) · Mettler-Toledo International Inc (MTD) · Quest Diagnostics Inc (DGX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades